Skip to main content

Cholesterol clinical trials at UCLA

3 in progress, 0 open to eligible people

Showing trials for
  • Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

    Sorry, in progress, not accepting new patients

    CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

    Torrance 5403022, California 5332921 and other locations

  • Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

    Sorry, in progress, not accepting new patients

    This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.

    Torrance 5403022, California 5332921 and other locations

  • Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

    Sorry, in progress, not accepting new patients

    Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

    Los Angeles 5368361, California 5332921 and other locations

Last updated: